Eloralintide vs Amylin
A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. Co-secreted with insulin; the satiety and gastric-emptying partner. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Eloralintide | Amylin IAPP | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Endogenous |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Selective long-acting amylin analog (acylated 37 aa peptide) | Islet amyloid polypeptide (37 aa) |
| Receptor / target | Amylin receptors (calcitonin receptor + RAMP), AMY1-selective | Amylin receptors (calcitonin receptor + RAMP complexes) |
| Molecular weight | ~4,526 Da | ~3,903.3 Da |
| Half-life | ||
| Based on | Amylin | Native hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Eloralintide and Amylin?
- Eloralintide is an engineered analog based on Amylin; Amylin is an endogenous hormone. Eloralintide signals at Amylin receptors (calcitonin receptor + RAMP), AMY1-selective; Amylin signals at Amylin receptors (calcitonin receptor + RAMP complexes).
- How do the half-lives of Eloralintide and IAPP compare?
- The reported circulating half-life of Eloralintide is ~13–15 days (310–366 h); Amylin is ~13 min (native). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Amylin vs Eloralintide. Or open the interactive comparison tool to add more molecules.